Becton Dickinson and (NYSE:BDX) Cut to “Hold” at ValuEngine

ValuEngine lowered shares of Becton Dickinson and (NYSE:BDX) from a buy rating to a hold rating in a research report report published on Thursday morning, ValuEngine reports.

Several other equities research analysts have also weighed in on BDX. KeyCorp reissued an overweight rating and issued a $262.00 price objective (down previously from $273.00) on shares of Becton Dickinson and in a report on Friday, May 10th. Barclays raised Becton Dickinson and from an equal weight rating to an overweight rating and set a $266.00 price objective for the company in a report on Monday, May 13th. BMO Capital Markets decreased their price objective on Becton Dickinson and from $272.00 to $270.00 and set a market perform rating for the company in a report on Friday, May 10th. Raymond James lifted their price objective on Becton Dickinson and from $265.00 to $288.00 and gave the stock a strong-buy rating in a report on Friday, June 28th. Finally, UBS Group decreased their price objective on Becton Dickinson and from $265.00 to $250.00 and set a neutral rating for the company in a report on Friday, May 10th. Five research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Becton Dickinson and currently has a consensus rating of Buy and an average target price of $265.00.

Shares of NYSE BDX traded down $3.66 during mid-day trading on Thursday, reaching $248.69. 1,166,959 shares of the company’s stock were exchanged, compared to its average volume of 816,174. The firm has a market cap of $68.07 billion, a price-to-earnings ratio of 22.59, a price-to-earnings-growth ratio of 1.87 and a beta of 1.11. Becton Dickinson and has a 52 week low of $208.62 and a 52 week high of $265.87. The company has a quick ratio of 0.59, a current ratio of 0.96 and a debt-to-equity ratio of 0.82. The stock has a 50-day moving average price of $250.17.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The company had revenue of $4.20 billion during the quarter, compared to analyst estimates of $4.25 billion. During the same quarter last year, the firm posted $2.65 EPS. The firm’s revenue for the quarter was down .6% on a year-over-year basis. On average, analysts expect that Becton Dickinson and will post 11.68 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, September 30th. Shareholders of record on Monday, September 9th will be issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a yield of 1.24%. The ex-dividend date of this dividend is Friday, September 6th. Becton Dickinson and’s payout ratio is presently 27.97%.

In other Becton Dickinson and news, EVP Samrat S. Khichi sold 16,085 shares of Becton Dickinson and stock in a transaction dated Tuesday, May 21st. The stock was sold at an average price of $234.68, for a total transaction of $3,774,827.80. Following the completion of the transaction, the executive vice president now owns 12,608 shares of the company’s stock, valued at approximately $2,958,845.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Patrick Kaltenbach sold 191 shares of Becton Dickinson and stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $241.03, for a total value of $46,036.73. Following the transaction, the executive vice president now directly owns 19,072 shares of the company’s stock, valued at approximately $4,596,924.16. The disclosure for this sale can be found here. Insiders have sold a total of 21,154 shares of company stock valued at $4,955,775 in the last ninety days. Insiders own 0.12% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. Duality Advisers LP grew its holdings in shares of Becton Dickinson and by 12.7% during the first quarter. Duality Advisers LP now owns 17,480 shares of the medical instruments supplier’s stock worth $4,365,000 after purchasing an additional 1,970 shares in the last quarter. Meridian Wealth Advisors LLC grew its holdings in shares of Becton Dickinson and by 2.7% during the first quarter. Meridian Wealth Advisors LLC now owns 3,787 shares of the medical instruments supplier’s stock worth $946,000 after purchasing an additional 99 shares in the last quarter. Pratt Collard Advisory Partners LLC grew its holdings in shares of Becton Dickinson and by 5.1% during the first quarter. Pratt Collard Advisory Partners LLC now owns 2,078 shares of the medical instruments supplier’s stock worth $519,000 after purchasing an additional 100 shares in the last quarter. Investec Asset Management North America Inc. grew its holdings in shares of Becton Dickinson and by 5.1% during the first quarter. Investec Asset Management North America Inc. now owns 11,123 shares of the medical instruments supplier’s stock worth $2,778,000 after purchasing an additional 543 shares in the last quarter. Finally, Black Diamond Financial LLC purchased a new position in shares of Becton Dickinson and during the second quarter worth about $562,000. 84.80% of the stock is owned by institutional investors and hedge funds.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Featured Article: What is net income?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.